Antibody molecules to cd138 and uses thereof

An anti-CD138 antibody molecule, which binds, or substantially binds, to an epitope on CD138, wherein the epitope comprises:

• (a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or more consecutive amino acid residues in an extracellular region proximal to the transmembrane domain of CD138;
• or
• (b) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or more consecutive amino acid residues in an extracellular region distant to the transmembrane domain of CD138, wherein the epitope does not consist of amino acid residues 107-111 of any of SEQ ID NOS:
• 1-3 or 450;
• or
• (iii) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or more consecutive amino acid residues in an extracellular region proximal to the transmembrane domain of CD138;
• and 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or more consecutive amino acid residues in an extracellular region distant to the transmembrane domain of CD138.

An anti-CD138 antibody molecule comprising one or both of:

• (a) a heavy chain variable region (VH), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises one, two, or all of the following:
• (i) an HCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the HCDR1 of an anti-CD138 monoclonal antibody selected from any of antibodies CD001, CD002, CD003, CD004, CD005, CD006, 602, 603, 604, 607, 613, 614, 617, 624, 632, 616, 619, 623, 1610, 2510, 2610, 2710, 2810, 2910, or 1409;
• (ii) an HCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the HCDR2 of the anti-CD138 antibody;
• or
• (iii) an HCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the HCDR3 of the anti-CD138 antibody;
• or
• (b) a light chain variable region (VL), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises one, two, or all of the following:
• (i) an LCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the LCDR1 of the anti-CD138 antibody;
• (ii) an LCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the LCDR2 of the anti-CD138 antibody;
• or
• (iii) an LCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence of the LCDR3 of the anti-CD138 antibody.

An anti-CD138 antibody molecule comprises:

• (I) (a) a heavy chain variable region (VH), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises:
• (i) an HCDR1 comprising an amino acid sequence of G-Y-N/S/T-F-S-S-Y (SEQ ID NO:
• 438);
• (ii) an HCDR2 comprising an amino acid sequence of H-P-S-D-S-T (SEQ ID NO:
• 351);
• or (iii) an HCDR3 comprising an amino acid sequence of F-V-Y;
• and (b) a light chain variable region (VL), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises one, two, or all of:
• (i) an LCDR1 comprising an amino acid sequence of R-S-S-K-S-L-L-Y-K-D-G-K-T-Y-L-N(SEQ ID NO:
• 352);
• (ii) an LCDR2 comprising an amino acid sequence of V-V-S-T-R-A-S(SEQ ID NO:
• 353);
• or (iii) an LCDR3 comprising an amino acid sequence of Q-Q-L-V-E-Y-P-Y-T (SEQ ID NO:
• 354);
• or
• (II) (a) a heavy chain variable region (VH), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VH comprises:
• (i) an HCDR1 comprising an amino acid sequence of S—Y-Y-M-H (SEQ ID NO:
• 380);
• (ii) an HCDR2 comprising an amino acid sequence of T-I-H-P-S-D-S-T-T-N-C/Y-N-Q-K-F-K-G (SEQ ID NO:
• 439);
• or (iii) an HCDR3 comprising an amino acid sequence of F-V-Y;
• and (b) a light chain variable region (VL), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), wherein the VL comprises one, two, or all of:
• (i) an LCDR1 comprising an amino acid sequence of R-S-S-K-S-L-L-Y-K-D-G-K-T-Y-L-N(SEQ ID NO:
• 352);
• (ii) an LCDR2 comprising an amino acid sequence of V-V-S-T-R-A-S(SEQ ID NO:
• 353);
• or (iii) an LCDR3 comprising an amino acid sequence of Q-Q-L-V-E-Y-P-Y-T (SEQ ID NO:
• 354).